A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 154,496 shares of TGTX stock, worth $2.75 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
154,496
Previous 41,835 269.3%
Holding current value
$2.75 Million
Previous $714,000 228.99%
% of portfolio
0.02%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$13.02 - $21.3 $1.47 Million - $2.4 Million
112,661 Added 269.3%
154,496 $2.35 Million
Q4 2023

Feb 14, 2024

SELL
$6.68 - $18.81 $352,871 - $993,638
-52,825 Reduced 55.8%
41,835 $714,000
Q3 2023

Nov 15, 2023

BUY
$8.36 - $26.5 $791,357 - $2.51 Million
94,660 New
94,660 $791,000
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $204,923 - $376,664
44,841 New
44,841 $265,000
Q4 2021

Feb 14, 2022

SELL
$15.2 - $35.51 $232,560 - $543,303
-15,300 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $98,532 - $182,995
-4,524 Reduced 22.82%
15,300 $509,000
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $644,280 - $970,583
19,824 New
19,824 $769,000
Q1 2021

May 17, 2021

SELL
$41.61 - $54.3 $665,052 - $867,876
-15,983 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $403,890 - $877,466
15,983 New
15,983 $831,000
Q2 2020

Aug 14, 2020

SELL
$8.9 - $21.84 $143,824 - $352,934
-16,160 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$7.14 - $15.99 $115,382 - $258,398
16,160 New
16,160 $159,000
Q2 2019

Aug 14, 2019

SELL
$6.27 - $8.65 $214,408 - $295,795
-34,196 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$4.02 - $8.04 $137,467 - $274,935
34,196 New
34,196 $275,000
Q4 2017

Feb 14, 2018

SELL
$7.35 - $12.3 $131,182 - $219,530
-17,848 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $178,480 - $226,669
17,848
17,848 $211,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $2.58B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.